Effects of 2',3'-dideoxycytidine and 2',3'-dideoxycytidine 5'-triphosphate on phospholipid metabolism in permeabilized rat hepatocytes

Biochemical Pharmacology

Volumn 54, Issue 6, 1997, Pages 713-719

  De Groote, Katrien ^a   Naesens, Lieve ^b   Balzarini, Jan ^b   Baes, Myriam I ^a   Declercq, Peter E ^a,c  

^a UNIVERSITY OF LEUVEN   (Belgium)

^b REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

^c Onderwijs en Navorsing ^*  (Belgium)

Author keywords

2',3' Dideoxycytidine; 2',3' Dideoxycytidine 5' triphosphate; Phosphatidylcholine; Phosphatidylethanolamine; Phospholipid; Rat hepatocyte

Indexed keywords

2',3' DIDEOXYCYTIDINE 5' TRIPHOSPHATE; NUCLEOSIDE ANALOG; PHOSPHATIDYLCHOLINE; PHOSPHATIDYLETHANOLAMINE; ZALCITABINE;

ANIMAL CELL; ARTICLE; COMPETITIVE INHIBITION; CONCENTRATION RESPONSE; CONTROLLED STUDY; DRUG EFFECT; LIVER CELL; MALE; NONHUMAN; PHOSPHOLIPID METABOLISM; PRIORITY JOURNAL; RAT;

ANIMALS; CELL MEMBRANE PERMEABILITY; CELLS, CULTURED; DEOXYCYTOSINE NUCLEOTIDES; LIVER; MALE; PHOSPHATIDYLCHOLINES; PHOSPHATIDYLETHANOLAMINES; RATS; RATS, WISTAR; ZALCITABINE;

EID: 0030869672     PISSN: 00062952     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-2952(97)00244-X     Document Type: Article

References (22)

1. Zeisel SH and Blusztajn JK, Choline and human nutrition. Annu Rev Nutr 14: 269-296, 1994.
2. Tijburg LBM, Geelen MJH and van Golde LMG, Regulation of the biosynthesis of triacylglycerol, phosphatidylcholine and phosphatidylethanolamine in the liver. Biochim Biophys Acta 1004: 1-19, 1989.
3. Tronchère H, Record M, Tercé F and Chap H, Phosphatidylcholine cycle and regulation of phosphatidylcholine biosynthesis by enzyme translocation. Biochim Biophys Acta 1212: 137-151, 1994.
4. Plagemann PGW, Wohlhueter RM and Woffendin C, Nucleoside and nucleobase transport in animal cells. Biochim Biophys Acta 947: 405-443, 1988.
5. Cooney DA, Dalal M, Mitsuya H, McMahon JB, Nadkarni M, Balzarini J, Broder S and Johns DG, Initial studies on the cellular pharmacology of 2′,3′-dideoxycytidine, an inhibitor of HTLV-III infectivity. Biochem Pharmacol 35: 2065-2068, 1986.
6. Whittington R and Brogden RN, Zalcitabine: a review of its pharmacology and clinical potential in acquired immunodeficiency syndrome (AIDS). Drugs 44: 656-683, 1992.
7. Dubinsky RM, Yarchoan R, Dalakas M and Broder S, Reversible axonal neuropathy from the treatment of AIDS and related disorders with 2′,3′-dideoxycytidine (ddC). Muscle Nerve 12: 856-860, 1989.
8. Stals HK, Mannaerts GP and Declercq PE, Factors influencing triacylglycerol synthesis in permeabilized rat hepatocytes. Biochem J 283: 719-725, 1992.
9. Stals HK, Top W and Declercq PE, Regulation of triacylglycerol synthesis in permeabilized rat hepatocytes: role of fatty acid concentration and diacylglycerol acyltransferase. FEBS Lett 343: 99-102, 1994.
10. Lind I, Ahnert-Hilger G, Fuchs G and Gratzl M, Purification of alpha-toxin from Staphylococcus aureus and application to cell permeabilization. Anal Biochem 164: 84-89, 1987.
11. Harshman S, Sugg N and Cassidy P, Preparation and purification of staphylococcal alpha toxin. Methods Enzymol 165: 3-7, 1988.
12. Zahlten RN and Stratman FW, The isolation of hormone-sensitive rat hepatocytes by a modified enzymatic technique. Arch Biochem Biophys 163: 600-608, 1974.
13. Seglen PO, Preparation of rat liver cells. Exp Cell Res 74: 450-454, 1972.
14. Kitos TE and Tyrrell DLJ, Intracellular metabolism of 2′,3′-dideoxynucleosides in duck hepatocyte primary cultures. Biochem Pharmacol 49: 1291-1302, 1995.
15. Cook HW and Spence MW, Dideoxycytidine, an anti-HIV drug, selectively inhibits growth but not phosphatidylcholine metabolism in neuroblastoma and glioma cells. Neurochem Res 14: 279-284, 1989.
16. Kanoh H and Ohno K, Solubilization and purification of rat liver microsomal 1,2-diacylglycerol:CDP-choline choline-phosphotransferase and 1,2-diacylglycerol:CDP-ethanolamine ethanolaminephosphotransferase. Eur J Biochem 66: 201-210, 1976.
17. Kent C, Regulation of phosphatidylcholine biosynthesis. Prog Lipid Res 29: 87-105, 1990.
18. Kelley JA, Litterst CL, Roth JS, Vistica DT, Poplack DG, Cooney DA, Nadkarni M, Balis FM, Broder S and Johns DG, The disposition and metabolism of 2′,3′-dideoxycytidine, an in vitro inhibitor of human T-lymphotrophic virus type III infectivity, in mice and monkeys. Drug Metab Dispos 15: 595-601, 1987.
19. Starnes MC and Cheng YC, Cellular metabolism of 2′,3′-dideoxycytidine, a compound active against human immunodeficiency virus in vitro. J Biol Chem 262: 988-991, 1987.
20. Balzarini J, Cooney DA, Dalal M, Kang GJ, Cupp JE, De Clercq E, Broder S and Johns DG, 2′,3′-Dideoxycytidine: regulation of its metabolism and anti-retroviral potency by natural pyrimidine nucleosides and by inhibitors of pyrimidine nucleotide synthesis. Mol Pharmacol 32: 798-806, 1987.
21. Chan TCK, Shaffer L, Redmond R and Pennington KL, Permeation and metabolism of anti-HIV and endogenous nucleosides in human immune effector cells. Biochem Pharmacol 46: 273-278, 1993.
22. Polas PJ, Swenson CL, Sams R, Cheney CM, Hayes KA, Tarr MJ, Kociba GJ and Mathes LE, In vitro and in vivo evidence that the antiviral activity of 2′,3′-dideoxycytidine is target cell-dependent in a feline retrovirus animal model. Antimicrob Agents Chemother 34: 1414-1421, 1990.